Cologuard Garners Another FDA Approval
The U.S. Food and Drug Administration approved Exact Sciences‘ Cologuard for use by eligible average-risk individuals ages 45 and older, the company announced today. Previously, the FDA had approved use…
The U.S. Food and Drug Administration approved Exact Sciences‘ Cologuard for use by eligible average-risk individuals ages 45 and older, the company announced today. Previously, the FDA had approved use…
Exact Sciences will acquire Genomic Health, a provider of genomic-based diagnostic tests that help optimize cancer care, in a cash and stock transaction valued at $2.8 billion, the company announced today. According to…
Exact Sciences opened its new 169,000-square foot clinical lab on the west side of Madison this week, the company announced recently. “Madison, Wisconsin is the home of earlier cancer detection,”…
Exact Sciences, along with the Mayo Clinic, reports that early research using blood-based methylated DNA markers demonstrate a potential to achieve 92% sensitivity and 92% specificity for detecting the most…
Exact Sciences announced today that former U.S. Department of Health and Human Services Secretary Kathleen Sebelius has joined its board of directors. “Secretary Sebelius understands the value of detecting cancer earlier, as…
More than two million Americans have been screened for colorectal cancer using Exact Sciences‘ Cologuard, the company announced today. “Cologuard is changing how Americans get screened for colorectal cancer and,…
Exact Sciences recently announced its latest financial report, which showed revenue of $454.5 million and 934,000 completed Cologuard tests during last year, an increase of 71 percent and 64 percent, respectively,…
Exact Sciences recently announced its fourth quarter numbers, which included revenues between $142.5 million – $143.5 million and 292,000 completed Cologuard tests, an increase of 64 percent and 66 percent…
Exact Sciences recently announced its third quarter numbers, which included revenue of $118.3 million and 240,000 completed Cologuard tests, an increase of 63 percent and 49 percent, respectively. “The Exact…
Exact Sciences strengthened its pipeline capabilities with its acquisition of Biomatrica, a provider of biological sample preservation technology, the company announced today. “To detect cancer at its earliest stages, you need…